Alembic Pharmaceuticals Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 3 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹16.1K Cr
U.S. U.S.
From Alembic Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹822
Market Cap
₹16.1K Cr
P/E Ratio
21.6
How does Alembic Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Alembic Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Alembic Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.8K Cr, net profit ₹202 Cr.
Full financials →📊 Revenue & Sales Performance
- →U.S. business expected to grow at a mid-teens constant currency rate (~10-15%) through FY '27 and '28, driven by volume growth and new launches despite pricing pressures.
- →ROW (Rest of World) markets saw 36% growth, indicating strong geographic expansion opportunities.
- →India branded business aiming to catch up with or exceed market growth by next fiscal year (FY '27), focusing on operational improvements and launches.
- →Upcoming launches in U.S., including the first branded product Pivya, expected to scale prescription share over 12–18 months, contributing to incremental revenue.
- →Injectable, peptides, drug-device combinations, and complex products targeted for growth over next 2-3 years.
- →R&D investments (~8-9% of revenue) support long-term pipeline and early-entry differentiated products.
- →Margin expansion expected from better capacity utilization to cushion expenses related to new product launches.
📈 Profitability & Margins
- →U.S. business is expected to grow at a mid-teens constant currency rate (10%-15%) in FY '27 and '28, driven by volume growth and new launches despite pricing pressures.
- →Margin expansion is anticipated in the current financial year due to better capacity utilization in existing facilities, expected to cushion expenses from the Pivya branded product launch.
- →The launch of Pivya, a first-line oral antibiotic in the U.S., will impact near-term profitability but is expected to scale up prescription share over 12-18 months, aiding medium- to long-term growth.
- →R&D investment will continue around 8%-9% of revenue, supporting differentiated products and pipeline development for sustained growth.
- →India domestic business growth is expected to improve and converge with market growth by Q1 FY '27, supported by operational execution and launches.
- →Overall margin improvement and operational excellence are driving EBITDA growth, with 25% EBITDA margin before R&D in Q3 FY '26 and sustained PAT growth of 21% year-on-year.
🏗️ Capital Expenditure Plans
- →No plans for large expansions currently, as per Shaunak Amin (Page 12).
- →Focus on better capacity utilization of existing facilities, expected to drive margin expansion in upcoming quarters (Page 14).
- →Strategic contracts and in-house products in injectable and oncology are expected to scale utilization of new facilities over next 12 to 18 months (Page 6).
- →Continued investment in R&D at around 8-9% of revenue, focusing on complex and differentiated areas like injectables, peptides, oral solids, and drug discovery (Pages 6, 10).
- →No explicit mention of new capital expenditure beyond optimizing and utilizing existing capacities and facilities.
- →Potential consideration of future expansion in the India market depending on operational outcomes (Page 12).
💰 Fundraising & Capital Structure
- →There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript.
- →Net debt has marginally declined to about INR 1,213 crores compared to the previous quarter, indicating no recent major debt raises.
- →The company focuses on operational performance, margin expansion, and R&D investment (around 8-9% of revenue) for growth.
- →No indications were given about upcoming equity issuance or fresh debt fundraising.
- →Management encourages shareholders and investors to reach out for clarifications but did not announce any fundraising plans during the call.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What Alembic Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Alembic Pharmaceuticals Ltd Q3 FY26 results?
U.S. U.S.
What is Alembic Pharmaceuticals Ltd share price analysis?
Alembic Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 21.6 with a market cap of ₹16,083 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alembic Pharmaceuticals Ltd planning capital expenditure?
No plans for large expansions currently, as per Shaunak Amin (Page 12).
Keep Alembic Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.